FDA approves three aNDAs for combination pain product from Accentia

By Lisa Kerner

Erie, Pa., May 8 - Accentia Biopharmaceuticals, Inc. and its development partner have received approval from the Food and Drug Administration for three additional combination pain product abbreviated New Drug Applications.

The company's wholly owned specialty pharmaceutical subsidiary, Teamm Pharmaceuticals, Inc., holds the exclusive U.S. license for the marketing and sale of these three new formulations, according to a company news release.

"The addition of these three new combination narcotic and analgesic products increases our comprehensive pain product portfolio to six, positioning the company to more effectively compete in an even larger segment of the chronic pain market," Teamm executive vice president of sales and marketing Gary Cantrell said in the release.

Located in Tampa, Fla., Accentia develops and commercializes late-stage clinical products in the therapeutic areas of respiratory disease and oncology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.